Aims/hypothesis. Whether excess glucose (glucotoxicity) and excess non-esterified fatty acids (lipotoxicity) act synergistically or separately to alter beta-cell function on Type 2 diabetes remains controversial. We examined the influence of non-esterified fatty acids, with or without concomitant increased glucose concentrations, on human islet function and on the expression of genes involved in lipid metabolism. Methods. Human islets isolated from non-diabetic and non-obese donors were cultured with 5.5, 16 or 30 mmol/l glucose, and when appropriate with 1 or 2 mmol/l non-esterified fatty acids. After 48 h, glucose-stimulated insulin secretion, insulin content, triglyceride content and expression of different genes were evaluated. Results. Non-esterified fatty acids decreased glucosestimulated insulin secretion, insulin content and increased triglyceride content of human isolated islets, independently from the deleterious effect of glucose. Increased glucose concentrations also decreased glucosestimulated insulin secretion and insulin content, but had no influence on triglyceride content. Glucose-stimulated insulin secretion of islets appeared to be significantly correlated with their triglyceride content. Glucose and non-esterified fatty acids modified the gene expression of carnitine palmitoyltransferase-I, acetyl-CoA carboxylase, acyl-CoA oxidase and uncoupling protein 2. Conclusion/interpretation. In our model of isolated human islets, increased glucose and non-esterified fatty acids separately reproduced the two major beta-cell alterations observed in vivo, i.e. loss of glucose-stimulated insulin secretion and reduction in islet insulin content. Our results also suggest that this deleterious effect was, at least in part, mediated by modifications in lipid metabolism gene expression. [Diabetologia (2004) 47:463-469] 
ity, was confirmed by in vitro exposure of isolated islets to NEFA [6, 7, 8] . However, whether glucose and NEFA alter beta-cell function synergistically or separately, remains controversial. Some authors have shown that beta-cell failure was induced by increased glucose alone [2, 9] or increased NEFA alone [6, 10] , while others have suggested that excess glucose or NEFA are not deleterious separately, but synergize in causing glucolipotoxicity [11, 12, 13, 14] .
Numerous studies have also shown that glucose and/or NEFA affect the expression of certain genes in islet cells. These include endocrine-specific genes such as insulin, glucagon, somatostatin and the glucose transporter GLUT2 [9, 15, 16, 17, 18] . Glucose and NEFA have also been shown to impair their own intraislet metabolism via changes in expression of genes encoding for key enzymes in glycolytic, lipogenic and fat oxidation pathways [9, 16, 19, 20, 21, 22, 23, 24, 25, 26, 27] . The expression of such transcription factors as pancreatic/duodenal homeobox-1 (PDX-1 or insulin promoter factor-1, IPF-1), peroxisome proliferator-activated receptor (PPAR) α and PPARγ, also appear to be modified by glucose and/or NEFA in pancreatic islets [9, 15, 16, 17, 18, 25, 26, 28] .
To date, most gene expression studies have been conducted in insulin-secreting cell lines or animal tissues. Results concerning beta-cell function and gene expression obtained in these various experimental models are contradictory. In this study, we examined the influence of NEFA on human islet function with or without concomitant increased glucose concentrations. Because lipid metabolism seems to have a crucial role in lipotoxicity [8] , we also studied the expression of genes involved in this metabolism.
Materials and methods
Human tissues and culture conditions. Human pancreata were harvested, in accordance with the Declaration of Helsinki, from brain-dead non-diabetic (mean HbA 1 c=5.03±0.09), and non-obese (mean BMI=24.2±1.5) adult donors. Islets were isolated by Liberase (Roche Diagnostics, Meylan, France) digestion using a slightly modified version of Ricordi's automated method [29, 30] . They were then purified using a continuous gradient density of Ficoll Separating Solution (Biochrom AG, Berlin, Germany). Islet preparations were cultured for 12 to 36 h in CMRL-1066 (Gibco BRL, Paisley, Scotland) containing 5.5 mmol/l glucose and supplemented with 10% FCS (Eurobio, Les Ullis, France), 100 UI/ml penicillin (Eurobio) and 100 µg/ml streptomycin (Eurobio). Islet preparations were then placed in CMRL-1066 medium containing 5.5, 16 or 30 mmol/l glucose, supplemented with 2% fatty acid-free BSA (Roche Diagnostics) and when appropriate with 1 or 2 mmol/l of a mixture of oleate/palmitate (2/1; Sigma Aldrich, Saint Quentin Fallavier, France). NEFA were added to the medium as ethanol solutions. Ethanol was eliminated by evaporation and NEFA were measured to check the concentration (Free Fatty Acid kit, Roche Diagnostics). Control media were supplemented with an equal volume of ethanol and underwent the same evaporation protocol.
Islet TG content. After 48 hours of culture in the different conditions, samples of islet preparations (n=3) containing 1000 islets with an equivalent diameter of 150 µmol/l were sonicated in NaCl 0.9% and TG content was assessed using the Trinder method (Triglycerides GPO-PAP kit, Roche Diagnostics), without extraction. The TG content was expressed as a ratio over DNA content, measured with the PicoGreen dsDNA Quantification kit (Molecular Probes, Leiden, The Netherlands).
Islet insulin content and secretion. Intracellular insulin content and glucose-stimulated insulin secretion (GSIS) were evaluated after 48 h of culture in the different conditions, on five distinct islet preparations. For intracellular insulin content, three samples of ten handpicked islets were sonicated in a lysis buffer (Tris HCl 10 mmol/l, EDTA 1 mmol/l) and insulin was extracted from secretion granules by overnight incubation in an extraction buffer (HCl 0.18 mol/l in 95% ethanol). To assess GSIS, static incubations were done in three batches of ten handpicked islets, for each condition of glucose and NEFA concentration. This step consists of 1 h preincubation with 2.8 mmol/l glucose, followed by three incubations of 1 h with 2.8 mmol/l glucose (basal 1), 25 mmol/l glucose (stimulation) and 2.8 mmol/l glucose (basal 2), respectively, in RPMI medium (Sigma Aldrich) containing 10% FCS. At the end of each incubation, RPMI was collected. Intracellular and secreted insulin were titered with the bi-insulin IRMA kit (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France). Insulin was expressed with reference to DNA content. The stimulation index was defined as the ratio of stimulated secretion to the mean of the two basal secretions.
Islet gene expression by quantitative RT-PCR.
For each islet preparation (n=5), samples of 2000 to 3000 islets were distributed over the varying conditions. After 48 h of culture, total RNA was extracted with the Nucleospin RNA II kit (Macherey Nagel, Hoerdt, France) and quantified with the RiboGreen RNA Quantification kit (Molecular Probes). First strand cDNA was synthesised from 1 µg RNA using M-MLV (Gibco BRL) primed with random hexamers (Roche Diagnostics), in an equal volume for each islet preparation sample.
The amplification was carried out in a 25 µl volume in 1X SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) containing 300 nmol/l of primers and 3 µl cDNA tenfold diluted after reverse transcription. The reaction consisted of 10 min at 95°C for activation of the AmpliTaq Gold DNA Polymerase and 40 cycles including 30 s denaturation at 95°C and 1 min annealing and extension at 60°C, and was achieved in the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Detection of PCR products was monitored at each cycle by measuring the increase in fluorescence caused by the binding of SYBR Green to double strand DNA. The threshold cycle (Ct) reflects the point at which a sufficient number of amplicons have accumulated to be statistically different from the baseline.
Primers were designed using the software Primer Express (Applied Biosystems). For each gene of interest, at least three couples of primers were tested for efficacy. Primers were selected only when their efficacy, calculated as described by the manufacturer, exceeded 95% (Table 1) .
For each gene of interest, samples of islet preparations in each condition were amplified in 96 well plates, concomitantly with specific primers for the gene of interest and for β-actin and 18S as internal standards. As described by the manufacturer, quantification requires the calculation of: (i) the mean Ct value of the replicate wells for each sample; (ii) the difference between the mean Ct values of the samples in the gene of in-terest wells and those of the internal standards (∆Ct); (iii) the difference between the mean ∆Ct values of the treated samples and the mean ∆Ct value of the non-treated (control) sample (∆∆Ct).
The relative quantitation value is expressed as 2 −∆∆Ct . Fig. 2 ). Significant reductions were also observed at 16 and 30 mmol/l glucose. The maximal effect was obtained for 2 mmol/l NEFA, which totally abolished the islet glucose response (stimulation index dropped to approximately 1). Glucose also reduced the islet stimulation index, in the absence of NEFA or in the presence of 1 mmol/l NEFA. At the concentration of 30 mmol/l glucose in the absence of NEFA, GSIS was signifi- cantly lower by 27.9% and 22.9% than at 5.5 and 16 mmol/l, respectively. Moreover, effects of NEFA and glucose seemed to be additive, since alteration of GSIS caused by 1 mmol/l NEFA was more important at 16 and 30 mmol/l glucose than at 5.5 mmol/l, though the difference was not statistically significant. Finally, a significant inverse correlation appeared between GSIS of islets and their TG content (r=0.747; p=0.018).
The insulin content of human islets cultured with 16 or 30 mmol/l glucose was significantly lower than with 5.5 mmol/l, since it decreased by 38.7% and 50.7%, respectively (Fig. 3) . Addition of 2 mmol/l NEFA to the culture medium also reduced insulin content of human islets by 21.0%, in the presence of 5.5 mmol/l glucose, but had no additional effect at higher glucose concentrations.
Islet gene expression. Modifications in glucose and
NEFA concentrations for 48 h had no influence on insulin, glucagon or glucokinase gene expression in human islets (Fig. 4) .
Carnitine palmitoyltransferase-I (CPT-I) expression was increased by NEFA (Fig. 4) . Two mmol/l NEFA increased CPT-I expression 2.8-, 3.9-and 5.4-fold, at 5.5, 16 and 30 mmol/l glucose, respectively. Glucose also influenced CPT-I expression, especially with a concomitant high concentration of NEFA. At 2 mmol/l NEFA, glucose increased CPT-I expression 1.7-and 2.1-fold at 16 and 30 mmol/l glucose, respectively. However this induction was not significant.
CPT-I expression was inversely correlated with GSIS (r=0.702; p=0.033) and correlated with TG content of islets (r=0.750; p=0.017).
The most noteworthy variation concerning acetylCoA carboxylase (ACC) was observed with the combination of 30 mmol/l glucose and 2 mmol/l NEFA, which increased ACC gene expression 1.7-fold, compared with 5.5 mmol/l glucose and no NEFA (Fig. 4) . Note, however, that ACC expression also increased with 16 mmol/l glucose and no NEFA, since it was 1.4-fold the level of ACC expression with 5.5 mmol/l glucose.
GLUT3, acyl-CoA oxidase (ACO) and uncoupling protein 2 (UCP-2) gene expression were similarly regulated by glucose and NEFA (Fig. 4) . The expression of these five genes increased with glucose concentration, in the absence of NEFA. Conversely, 1 and 2 mmol/l NEFA decreased their expression when combined with high glucose concentrations (16 and 30 mmol/l).
In contrast to GLUT3, GLUT1 expression was increased by NEFA at 16 and 30 mmol/l glucose (Fig. 4) .
Discussion
Type 2 diabetes results from the failure of beta-cells to compensate for increased insulin secretory demand [1] . Increased glucose and NEFA seem to actively contribute to beta-cell function alteration, and their albumin concentration was used to obtain an appropriate albumin to NEFA ratio. It is indeed important to note that the effect of NEFA on beta-cells can differ with NEFA subtypes: it was suggested that saturated NEFA, such as palmitate, impaired beta-cell function and viability whereas monounsaturated NEFA, such as oleate, can prevent this deleterious effect [33, 34] . Using a mixture of oleate and palmitate, our model did not distinguish the effect of each NEFA subtype, but tended to reproduce the plasmatic mixture of NEFA that exists in vivo. This methodological difference could explain some of the discrepancies between our results on gene expression and others, which in most cases used palmitate alone. With our model of in-vitro human islets, we showed that beta-cell alterations characteristic of clinical Type 2 diabetes, including loss of GSIS and decrease in insulin content, can be reproduced with either increased glucose or NEFA concentrations. The deleterious effect of high glucose is well established [2, 3] , but increased NEFA at physiological glucose concentrations were also able to significantly alter GSIS and insulin content. These results are in accordance with previous studies [6, 10, 33] , but argue against the hypothesis that increased glucose is a prerequisite for the deleterious effect of NEFA on betacell function [11, 12, 13, 14] . We also found that in-action is, at least in part, mediated by modifications in gene expression [9, 17] . We studied the respective influence of glucose and NEFA on human islet function and several gene expressions. Both increased glucose and NEFA separately mimicked the two major betacell alterations observed in vivo, i.e., loss of GSIS and reduction in islet insulin content. The effects of glucose and NEFA were also partially additive. Functional alterations were associated with intracellular accumulation of TG and modifications of certain islet gene expressions.
In vivo, the normal plasma concentration of NEFA is less than 0.6 mmol/l, but could exceed 1 mmol/l in Type 2 diabetic patients [31, 32] . Palmitate and oleate are the two most represented NEFA in plasma (20 to 25% each) and circulate linked to albumin. To mimic what is observed in vivo, we used a mixture of oleate and palmitate with 2% fatty acid-free BSA. This high creased glucose and NEFA have additive effects since their combination led to more pronounced deterioration of beta-cell function.
Increased NEFA concentrations induced constant decrease in GSIS but inconstant decrease in insulin content, and had no influence on insulin gene expression, as described in certain studies [35] , in contrast to others [17, 18] . Those results suggested that NEFA could probably act via pathways not related to betacell exhaustion, by inducing for example overexpression of hormone-sensitive lipase [36] or change in signal recognition not yet clearly understood [37] .
In accordance with these studies, increased NEFA induced TG accumulation in islets, which was inversely correlated with GSIS. As shown previously [38] , a chronic increase in fatty acids, enhances insulin basal secretion (hence diminushing GSIS) by stimulating fatty acyl-CoA that acts distally and in turn stimulates the exocytic machinery. In accordance with previous studies, NEFA concentrations appeared also linked to CPT-I expression in human islets, [22, 35] . CPT-I's involvement in fatty acid penetration into the mitochondria [39] , plays a central role in the repartition of fatty acids between mitochondrial oxidation and their accumulation as long chain fatty acyl-CoA or complex lipids in the cytoplasm. The marked increase in CPT-I expression induced by NEFA, and its negative correlation with GSIS suggest that CPT-I could exert a central role in the loss of beta-cell signal recognition induced by NEFA. Those results are concordant with the glucose fatty acid cycle reported in rat islets [6, 7, 10] . This hypothesis proposes that an increase in NEFA oxidation leads to a decrease in glucose metabolism in beta-cells, according to the Randle cycle observed in other tissues [40] . The consequence is a reduction in insulin secretion, since it is linked to glucose oxidation. This hypothesis is supported by (i) the restoration of insulin secretion by inhibition of NEFA oxidation and (ii) the specificity of the altered response to glucose, as opposed to other secretagogues [6, 7, 10] . We report, however, that the concomitant presence of increased glucose and NEFA also induced ACC gene expression in islets. ACC induces the inhibitor of CPT-I, malonyl-CoA, and is also critical for the regulation of fatty-acid balance between oxidation and cytoplasmic accumulation. At this time, the effect of NEFA on ACC expression is still controversial [20, 35, 38, 41] . So, complementary studies exploring enzymatic activity of CPT-I and NEFA oxidation are necessary to determine the precise interaction between CPT-I and ACC and their regulation by glucose and NEFA.
In conclusion, we found in our model of isolated human islets that exposure to increased glucose or to a mixture of palmitate and oleate independently reproduced some of the islet anomalies observed in Type 2 diabetes in vivo, i.e. loss of GSIS, decrease in islet insulin content and islet TG accumulation. Our results also suggested that this deleterious effect was, at least in part, mediated by modifications in the expression of genes implicated in lipid metabolism.
